Systemic lupus erythematosus (SLE) is a chronic, autoimmune disorder characterized by a broad spectrum of clinical manifestations with multiple autoantibody production and complement-fi xing immune complex deposition that result in tissue' damage. 1 Although the specifi c cause of SLE is unknown, several studies associate this disease to defective cellular and humoral immunity, probably infl uenced by genetic, environmental, and hormonal factors. 2, 3 Free radicals and other reactive oxygen/nitrogen/chlorine species are believed to contribute to the development of several chronic diseases by causing oxidative stress and oxidative damage. Diseases in which oxidative damage has been implicated include cancer, atherosclerosis, Alzheimer's disease, diabetes mellitus, and autoimmune diseases. [4] [5] [6] [7] [8] Most clinical studies focus on the measurement of oxidative damage by using biomarkers -oxidants and antioxidants. Malondialdehyde (MDA), an oxidation product of lipoperoxidation, has been found elevated in various diseases.
9 Sulfhydryl (SH) groups (thiols) are considered the biggest and most frequently antioxidants in plasma. 10 Several experimental studies pointed to a qualitatively and quantitatively important role of uric acid as an antioxidant substance acting as a free radical scavenger and a chelator of transitional metal ions which are converted to poorly reactive forms.
11
The purpose of this study was to determine the presence of oxidative stress in SLE patients by determining these biomarkers in blood samples. Parameters were correlated with disease activity and comorbidities; results were compared with normal subjects in the control group.
The study included 36 patients with SLE and 28 healthy volunteers (control) between the ages of 10 and 56. The diagnosis was based on at least four of the 11 diagnostic criteria established by the American College of Rheumatology (ACR). 12 All patients were in treatment and the disease activity was assessed by the Systemic Lupus Erythematosus Disease Active Index (SLEDAI). Disease was considered active when SLEDAI > 6. 13 The protocol of the study was approved by the Ethical Committee for Human Research from Universidade Federal do Amazonas (CAAE n. 0043.0.115.000.08). All patients and non-patients signed an informed consent form before taking part in the study and were submitted to a standardized questionnaire for demographic factors.
The venous blood collection (10 mL) from each participant was done with an evacuated tube system (BD Vacutainer® System) and centrifuged (800 g, 15 min). Serum was used for determining biochemical and immunological markers.
MDA was determined by High Performance Liquid Chromatography (HPLC); chromatograms were monitored at 532 nm and the sample concentration was determined in µmol/L.
14 Uric acid was measured using Cobas Mira® spectrophotometric analyzer (Roche Instruments Inc.), with commercially available kits (Labtest, Minas Gerais, Brazil). SH groups were determined by the Ellmans method, modifi ed by Hu et al. 15 The results were expressed as means ± standard deviation (SD). Student's t-distribution was used to compare mean values. Pearson's and Spearman's correlations were applied to correlate the parameters with SLEDAI. P < 0.05 was considered to be statistically signifi cant.
General and demographic characteristics of SLE patients and healthy controls are presented in Table 1 . There was also no difference between duration, criteria number, and activity of the disease and oxidative stress (P > 0.05).
Lupus is characterized by direct aggression of autoantibodies and complement-fi xing immune complex deposition that result in tissues' damage associated to oxidative stress. 16 Waszczykowska et al., 17 suggested that intracellular free radicals are capable of inducing cytokine synthesis that participate and modulate infl ammatory responses with the creation of superoxide radicals.
Oxidative stress, measured by MDA levels, was found increased in 78.9% (n = 30) of SLE patients, while only 21.1% (n = 8) of normal controls presented that increase (OR = 12.5; 95% CI 3.7-41.5). As shown in Table 2 , MDA levels were found to be signifi cantly increased in SLE patients compared to normal controls. No signifi cant difference was found between MDA levels and the duration of the disease or comorbidities. Increased level of MDA in the serum 18 and in the erythrocytes 19 was reported in SLE patients. Wang et al. 20 and Shah et al. 21 associated stronger oxidative stress response with higher SLEDAI scores, similar to the previous report of Tewthanom et al. 18 However, we have not identifi ed, in our study, the association of MDA or SH levels with SLEDAI scores. The high levels of MDA in SLE patients indicate that the lipid cell membrane was attacked and that MDA can be a good marker of oxidative stress in this disease.
There was no signifi cant change in serum levels of uric acid in SLE patients compared to normal controls (4.1 ± 1.5 and 3.8 ± 0.9 mg/dL, respectively). No correlation was found between the serum levels of this compound and disease activity. Deminice et al. 22 associated uric acid as an oxidative stress biomarker response to an acute session of hypertrophy-resistance traditional interval training and circuit training. Ikeda et al. 23 , however, could not make the same association when oxidative stress was observed in patients with progressive amyotrophic lateral sclerosis. Although uric acid is consider an important antioxidant and its serum levels were expected to be lower in SLE patients than in normal controls, our study could not associate this substance as a secure biomarker of oxidative stress either.
Morgan et al. 24 showed that markers of protein oxidation correlate with worsening disease status in SLE. In our study, SH group levels were found to be signifi cantly decreased in SLE patients compared to normal controls (260.2 ± 182.7 versus 339.4 ± 104.3 µmol/L), similar to the report of Zhang et al. 25 This supports the role of oxidative stress in the pathogenesis of SLE.
We concluded that SLE patients present increases in oxidative stress. However, this response is not correlated to the disease activity or its duration. MDA and SH group levels can be used as biomarkers to measure oxidative stress in SLE patients, whereas uric acid cannot be used for the same purpose. Further studies on oxidative stress and SLE are still necessary to improve our understanding of the disease pathogenesis. Values are expressed as mean ± SD and the differences were considered signifi cant when P < 0.05.
